Related Experiment Video
Updated: May 24, 2025

Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Non-islet cell tumor hypoglycemia (NICTH) associated with sarcoma, case report
Atefeh Jannatalipour1,2, Nekoo Panahi3,4, Mahnaz Pejman Sani5,6
1Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome caused by the secretion of high molecular weight insulin-like growth factor II (IGF-II) from tumors, particularly those of mesenchymal and epithelial origin. This case report describes a 71-year-old male with pelvic sarcoma who presented with severe hypoglycemia, with blood glucose levels dropping below 40 mg/dL and exhibiting neuroglycopenic symptoms. The diagnosis of NICTH was confirmed through biochemical analysis showing hypoinsulinemic hypoglycemia alongside low C-peptide and IGF-1 levels. Initial management with dextrose infusions and glucocorticoids proved ineffective until recombinant human growth hormone (rhGH) therapy was initiated, resulting in a decreased requirement for dextrose. Following angioembolization of the tumor, the patient's blood glucose levels stabilized sufficiently to allow for the complete cessation of dextrose administration. This case highlights the critical role of rhGH in reducing dextrose dependency and the effectiveness of angioembolization in managing NICTH when surgical options are limited.
Related Concept Videos
Hypoglycemia and Glucagon
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational

